PharmaPath, owned by Irini, Petros, and Eugenia Vasilopoulou, has announced the successful completion of its acquisition of Innovis Pharma, building on an initial agreement made in December 2025. This strategic merger is set to redefine the landscape of the domestic and international pharmaceutical market, forming a new comprehensive Greek pharmaceutical group with over 450 employees. The new entity promises to combine high specialization in research and development with strong production capabilities and commercial excellence.

Reports suggest that Alpha Bank was the exclusive financier for this transaction, having supported PharmaPath from the beginning with the aim of furthering the company's growth trajectory. This initiative is expected to bolster the domestic pharmaceutical sector while enhancing the global presence of Greek enterprises. The backing from Alpha Bank underlines the confidence in PharmaPath's potential to lead and innovate in the competitive pharmaceutical landscape.

PharmaPath has been active in the development, production, and marketing of pharmaceutical, para-pharmaceutical, cosmetic, and dietary products since its establishment in 2017. As the newly created group integrates its operations and resources, it will likely play a vital role in advancing local innovation and providing a broader range of products in both domestic and international markets, highlighting the strategic importance of this acquisition for the future of the Greek pharmaceutical industry.